Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma

Table 1 Relationship between clinicopathologic features and IL-12 or IL-18 expression in gastric carcinoma (n = 50)

Variables		n	IL-12		IL-18
			Positive (%)	P	Positive (%)	P
Gender	M	34	14 (41.2)	0.558	10 (29.4)	0.5081
	F	16	8 (50.0)		3 (18.8)
Age (yr)	< 60	25	14 (56.0)	0.087	7 (28.0)	0.747
	≥ 60	25	8 (32.0)		6 (24.0)
Differentiated	Well	12	2 (16.7)	0.029	3 (25.0)	1.0001
	Poorly	38	20 (52.6)		10 (26.3)
pT category	T1-2	24	5 (20.8)	0.002	4 (16.7)	0.148
	T3-4	26	17 (65.4)		9 (34.6)
pN category	N0	26	6 (30.8)	0.002	6 (23.1)	0.624
	N1-3	24	16 (66.7)		7 (29.2)
pM category	M0	40	13 (32.5)	0.0031	6 (15.0)	0.0011
	M1	10	9 (90.0)		7 (70.0)
TNM stage	I-II	28	7 (25.0)	0.005	6 (21.4)	0.406
	III-IV	22	15 (68.2)		7 (31.8)

¹Fisher’s exact probability test.

Table 2 Relationship between IL-12 and IL-18 expressions in gastric carcinoma

Variables	IL-18 (+)	IL-18 (-)	Patients (n)	P
IL-12 (+)	8	14	22	0.139
IL-12 (-)	5	23	28
No. of patients	13	37	50

Table 3 Multivariate analysis for overall survival in gastric carcinoma

Variables	B	SE	Wald	df	P	Exp (B)	95% CI
IL-12	0.955	0.237	16.290	1	< 0.001	2.599	1.634-4.132
MVD	0.897	0.390	5.287	1	0.021	2.452	1.142-5.268
T stage	0.786	0.349	5.076	1	0.024	2.194	1.108-4.347